H.C. Wainwright Reiterates a Buy Rating on Correvio Pharma Corp (CORV)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Correvio Pharma Corp (CORV), with a price target of $7. The company’s shares closed last Monday at $1.68, close to its 52-week low of $1.43.
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -12.5% and a 27.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Correvio Pharma Corp is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
Based on Correvio Pharma Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $10.47 million. In comparison, last year the company had a net profit of $5.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.